Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579237 | 0.78 | CTSS (0.30) | NLRP3 | |
| SCHEMBL67104 | 0.71 | CYP3A4 (0.35) | KDM1A | |
| SCHEMBL668941 | 0.71 | CA1 (0.50) | KDM1A | |
| SCHEMBL10321356 | 0.71 | ALDH1A1 (0.35) | KDM1A | |
| SCHEMBL13194108 | 0.71 | KDM1A (0.33) | KDM1A | |
| SCHEMBL23126916 | 0.71 | KDM1A (0.35) | KDM1A | |
| SCHEMBL67103 | 0.71 | KDM1A (0.33) | KDM1A | |
| SCHEMBL27819766 | 0.71 | KDM1A (0.33) | KDM1A | |
| SCHEMBL21386243 | 0.70 | KDM1A (0.32) | KDM1A | |
| SCHEMBL18205516 | 0.70 | NPY5R (0.35) | KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-04-23 | — | — | US | disclosed |
| US-7491794-B2 | Macrocyclic compounds as inhibitors of viral replication | INTERMUNE, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1749007-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | Intermune, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | HOFFMANN-LA ROCHE INC. | 2005-12-01 | — | — | US | disclosed |
| WO-2005095403-A2 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111982-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | PARG 2899/4885PDE4A 3226/4885PDE4B 2667/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | PARG 2899/4885PDE4A 3226/4885PDE4B 2667/4885 |
| US-20090111969-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | PARG 2899/4885PDE4A 3226/4885PDE4B 2667/4885 |
| US-20050267018-A1 | Macrocyclic compounds as inhibitors of viral replication | EIF2AK2, HAVCR2, ZC3HAV1 | PARG 2899/4885PDE4A 3226/4885PDE4B 2667/4885 |
| US-20090105471-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | PARG 2899/4885PDE4A 3226/4885PDE4B 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.